Dihydropynmidine dehydrogenase deficiency is diagnosed more frequently and is now generally accepted as a potentially life-threatening condition It predisposes patients receiving treatment with fluoropynmidines such as 5-fluorouracil (5-FU) to severe and, in case of complete dihydropynmidine dehydrogenase deficiency, often fatal toxicity A patient who had severe side effects following standard dose adjuvant 5-FU exposure was diagnosed of having hereditary partial dihydropynmidine dehydrogenase deficiency When the patient relapsed with liver metastases, we treated him with the non-fluoropyrltnidine cytotoxic agents irinotecan, oxaliplatin and raltitrexed in sequential manner, and were able to show that these drugs can be safely applied in patients with this metabolic defect
Introduction
Colorectal cancer is the most prevalent gastrointestinal malignancy and second leading cause of cancer death in many industrialized countries. When diagnosed at an early stage, colorectal cancer can be cured by surgery alone. In more advanced but resectable stages, surgery is usually combined with adjuvant chemotherapy or chemoradiation 5-fluorouracil (5-FU) is the drug of choice in both the adjuvant and palliative setting Nearly half of all patients with colorectal cancer develop a local relapse, synchronous or metachronous metastasis, and do require systemic treatment.
For the past four decades, 5-FU and other fluoropyrimidine antimetabohtes have been the mainstay of treatment for patients with metastatic or irresectable disease More recently, topoisomerase I-inhibitors, new platinum compounds and other agents were found to have significant antineoplastic activity in this common tumor type.
Dihydropynmidine dehydrogenase (DPD) is the initial and rate-limiting enzyme in the catabolism of 5-FU [1] . It catabolizes more than 80% of the administered dose to inactive or even toxic metabolites.
Patients with a complete or near-complete deficiency of the enzyme do suffer from severe toxicity following the administration of standard doses of fluoropynmidines, due to significantly increased and prolonged plasma levels of 5-FU [2-4] The incidence of this pharmacogenetic syndrome in the general population is estimated to be as high as 3% and may be much more common than originally thought [5] The use of fluoropyrimidines in patients with this metabolic defect is associated with a very high mortality [3] . A standard salvage treatment for the underlying malignancy in patients with inherited DPD-deficiency is yet to be defined.
The camptothecine derivative irinotecan, a DNA topoisomerase I-inhibiting agent, was shown to have activity against colorectal cancer [6] . The drug lacks cross-resistance with 5-FU and is now commonly used for first-or second-line treatment of metastatic disease Oxaliplatin, a diaminocyclohexane platinum derivative, has impressive anticancer activity when used in combination with 5-FU and fohnic acid as first-line chemotherapy, and activity has also been seen when used as single agent in this tumor type [7] . Raltitrexed, a quinazoline folate analogue, was developed as a direct and specific thymidylate synthase inhibitor that lacks the non-specific effects on RNA and protein synthesis which are often observed for 5-FU [8] . Raltitrexed is now available for treatment of colorectal cancer in many countries. All these novel agents could be considered as salvage treatment options for patients with defects in the 5-FU metabolism related to DPD deficiency.
This case report describes the sequential palliative use of single-agent irinotecan, oxaliplatin and raltitrexed in a partially DPD-deficient patient with a hepatic relapse of colorectal cancer, who experienced hfe-threatening 5-FU-related toxicity during standard adjuvant chemotherapy.
Clinical evaluation
A 59-year-old Caucasian male was diagnosed with a moderately differentiated adenocarcinoma of the ascending colon and underwent a right hemicolectomy and lymphadenectomy in October 1999. The tumor was classified as pT3pN 2 M 0 , grade 3 and grouped as UICC stage III. Standard adjuvant treatment with 5-FU and folinic acid was initiated within two weeks after surgery 5-FU (425 mg/m 2 ) and folinic acid (20 mg/m 2 ) were given as an l v bolus on days 1-5. The in-patient treatment was initially tolerated well and he was discharged after the last application of the first treatment cycle on October 29, 1999 On November 3 he presented with severe stomatitis and dysphagia and had to be re-admitted to the hospital During the first two weeks of this longterm hospitahzation, the patient's condition worsened progressively The stomatitis did not improve despite local therapy. He developed severe bone marrow depression with peripheral pancytopenia. Due to febrile leukopenia with temperatures up to 39 3°C on November 6, treatment with antibiotics and granulocyte-colony stimulating factor was initiated. The further course was complicated due to pneumonia, repeated aspiration and respiratory insufficiency requiring mechanical ventilation Furthermore he developed left cardiac insufficiency of unknown etiology After gradual improvement, the patient left the intensive care unit and was discharged in good condition on December 21. No further adjuvant chemotherapy was administered, and the patient was followed closely.
The severe toxicity observed during the first cycle of standard 5-FU-treatment rose suspicion of a defect in drug metabolism As we expected a hereditary genetic defect, punne and pynmidine metabolites and DPDactivity were determined in urine and plasma of the patient and his healthy son according to methods previously described [9] (Table 1) . Uracil and uric acid were mildly elevated in plasma samples of the patient, whereas thymine, 5-OH-methyluracil, hypoxanthine and xanthine were within the normal range (data not shown). DPD activity was present in mononuclear cells of the patient, but was decreased compared to that of healthy controls (n = 21) and was comparable to the DPD activity observed in obligate heterozygote individuals (n = 13). The son had decreased DPD activity in mononuclear cells as well, which was comparable to obligate heterozygotes. Based on these findings, both father and son were diagnosed of having a hereditary form of partial DPD deficiency.
In February 2000 the patient was complaining of fatigue and abdominal pain. A CT scan revealed metachronous inoperable liver metastases, confirmed by a significant rise in serum CEA In order to avoid the further administration of fluoropynmidines, we suggested palliative treatment with single agent lnnotecan, which was then safely administered over three consecutive cycles at a dose of 125 mg/m 2 as a 30-minute I.V infusion on days 1, 8, 15, 22 Control group (mean ± SD) 10 0 ± 3 4
Obligate heterozygotes (mean ± SD) 5 5 ± 2 1 every six weeks Concomitant medication included ondansetron, atropine and loperamide. No severe or unexpected side effects were observed during the course of treatment, only mild diarrhea (common toxicity criteria (CTC) grade 1), nausea (CTC grade 1) and abdominal cramping (CTC grade 1) did occur When the liver metastases did increase in number and size after the third treatment cycle, we offered further palliation with single agent oxahplatin, given at a dose of 85 mg/m" as a 120-minute infusion every two weeks. Concomitant medication consisted of ondansetron and metoclopramide. The patient was treated with this agent over 12 weeks. Nausea (CTC grade 1), paresthesia of the fingertips (CTC grade 1) and cold dysesthesia (CTC grade 1) were observed as expected, mild and fully reversible side effects. When re-evaluated with CTscan at week 12, the liver metastases had progressed further with a significant increase in size The highly motivated patient, still in good condition, was then started on treatment with raltitrexed at a dose of 3 mg/m 2 given every two weeks, which was given without severe toxicity. The latest evaluation of response indicates disease progression in the liver after six cycles
Discussion
Although complete DPD deficiency is known to be a rare finding, 3% of non-selected cancer patients exhibit a partial deficiency in activity of this catabolic enzyme They are at increased risk of developing fluoropynmidinerelated toxicity [5] . An incidence of this pharmacogenetic syndrome as high as 5.8 % was recently reported in a series of breast cancer patients [10] It is well known that the physiological DPD activity has a strong interpatient and intraindividual variation [11] . The enzyme activity appears to be unrelated to age, sex, race, or stage of disease. There are several reports on variable mutations in the DPD gene, but up to now, there is no clear correlation between genotype and phenotype, i.e., specific mutations in the DPD gene do not predict the extent in DPD deficiency [12, 13] . It has been shown that the inheritance of some mutations associated with DPD deficiency does follow an autosomal recessive pattern [2, 13] .
The liver is known to be the main location of fluoro-pynmidine catabolism Considering the similar distribution pattern of DPD activity in peripheral mononuclear cells and liver, the enzyme activity in peripheral blood cells is commonly suggested as a marker for DPD activity in general The determination of DPD activity could be used to avoid excessive 5-FU toxicity in patients at risk. There are a number of smaller series on 5-FU-induced toxicity in DPD-deficient patients. These cases usually present with severe mucositis/stomatitis, diarrhea and/or myelotoxicity. Cardiotoxicity, hypertension, alopecia and neurotoxicity presenting as stupor, confusion or encephalopathy have been described less frequently A 33% mortality following 5-FU exposure was reported in a series of patients with partial DPD-deficiency [3] .
Although a specific screening method for disorders of the purine and pynmidine metabolism has been established, detection of heterozygotes remains problematic [14] . Therefore, most DPD-deficient patients will still be detected when developing severe toxicity after exposure to fluoropynmidines.
Up to now, there is no specific treatment for 5-FUrelated toxicity due to DPD-deficiency. Furthermore, there is no published report on the safety and efficacy of salvage chemotherapy in this group of patients With the recent availability of non-fluoropynmidine agents with proven antineoplastic activity in colorectal cancer, treatment alternatives to 5-FU may be considered even in case of a known defect in the pynmidine metabolism. Innotecan, oxahplatin and raltitrexed are known to have activity both as single agent and in combination with 5-FU and are not cross-resistant with fluoropynmidines.
Innotecan is converted to the active metabolite SN-38 by the enzyme carboxylesterase. SN-38 binds to topoisomerase I and forms in conjunction with DNA the so-called cleavable complex and disturbes tumour cell proliferation by inhibiting topoisomerase I [15] . The antineoplastic activity of the diaminocyclohexane platinum denvate oxaliplatin is mediated through the formation of DNA-adducts, as with other platinum compounds. Raltitrexed is a substrate for the enzyme polyglutamate synthase, which converts the drug into a polyglutamate form. The polyglutamates act as a specific inhibitors of the thymidylate target enzyme.
Therefore, DPD is not involved in the metabolism of mnotecan, oxaliplatin and raltitrexed and it may be assumed that all these agents could be applied safely in patients with DPD-deficiency We were able to confirm this assumption in a single patient Treatment with irinotecan, oxaliplatin and raltitrexed given in a sequential manner was well tolerated and no severe, unexpected, cumulative or persistent toxicity was observed. Unfortunately, though, no antineoplastic activity was seen in our patient To confirm the safety of this approach, we would like to suggest to perform prospective studies with the newer agents involving an adequate number of individuals with this pharmacogenetic syndrome. 
